



(12) Translation of
European patent specification

(11) NO/EP 4003533 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 38/00 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.06.10
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.03.13
(86)	European Application Nr.	20757443.5
(86)	European Filing Date	2020.07.30
(87)	The European Application's Publication Date	2022.06.01
(30)	Priority	2019.07.31, US, 201916528390
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Nymox Corporation, 777 Terrace Avenue, Hasbrouck Heights, New Jersey 07604, USA
(72)	Inventor	AVERBACK, Paul, Princesse Charlotte 13, 98000 Monaco, Monaco
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54)	Title	METHODS OF TREATING MULTIFOCAL CANCER
(56)	References Cited:	SHORE NEAL ET AL: "Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia", THERAPEUTIC ADVANCES IN UROLOGY, SAGE PUBLICATIONS LTD, GB , vol. 11 31 December 2018 (2018-12-31), page 1756287218, XP009523260, ISSN: 1756-2872, DOI: 10.1177/1756287218820807 Retrieved from the Internet: URL: http://journals.sagepub.com/doi/full-x ml/10.1177/1756287218820807 [retrieved on 2019-01-14] Anonymous: "Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study", , 9 February 2016 (2016-02-09), XP055404013, Retrieved from the Internet: URL: http://money.cnn.com/news/newsfeeds/ar ticles/globenewswire/6174512.htm [retrieved on 2017-09-05]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Sammensetning som omfatter en terapeutisk effektiv mengde av Fexapotidtriflutat (FT) for bruk i en fremgangsmåte for å redusere multifokal kreftforekomst, redusere multifokal kreftgrad og redusere multifokal kreftprogresjon i hele prostata hos et pattedyr som har lavgrads unifokal prostatakraft, hvori fremgangsmåten omfatter:

identifisere et pattedyr som har en unifokal kreftsvulst;
administrering til den unifokale kreften av sammensetningen, hvori sammensetningen administreres ved injeksjon direkte til den unifokale kreftsvulsten.

2. Sammensetning for bruk ifølge krav 1, hvori den terapeutisk effektive mengden av fexapotidtriflutat er innenfor området fra ca. 2,5 mg til ca. 20 mg.

3. Sammensetning for bruk ifølge krav 1, hvori den terapeutisk effektive mengden av fexapotidtriflutat er innenfor området fra ca. 2,5 mg til ca. 15 mg.

4. Sammensetning for bruk ifølge krav 1, hvori den terapeutisk effektive mengden av fexapotidtriflutat er 15 mg.